# OncoExTra

Source: https://onco.cc/drugs/oncoextra/  
OnCo record `oncoextra` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Exact Sciences' tissue test for advanced solid tumours that reads every gene's DNA and RNA and compares the tumour with the patient's normal DNA.

## Summary

OncoExTra is Exact Sciences' comprehensive genomic profiling test for advanced, metastatic, refractory, relapsed or recurrent solid tumours. It sequences the whole exome of the tumour against a matched normal sample and the whole transcriptome of the tumour, and reports mutations and fusions associated with FDA-approved therapies, tumour mutational burden and microsatellite status, and clinical trial options. Exact Sciences cites the 2021 validation of GEM ExTra as the test's own validation: that assay detects single-nucleotide variants, insertions and deletions, focal copy number changes and the TERT promoter region, and its RNA sequencing finds fusions and transcripts such as AR-V7, EGFR vIII and MET exon 14 skipping. In a retrospective analysis of 1,509 reports that Exact Sciences quotes, 83.9% showed at least one clinically actionable variant. The test was developed by Genomic Health, an Exact Sciences subsidiary, is performed at its Phoenix laboratory, and has not been cleared or approved by the FDA.

## Fields

- Kind: Test
- Status: established
- Last checked: 2026-11-03
- Also known as: Exact Sciences OncoExTra
- Tags: test
- Brand: OncoExTra
- Modality: Tumour profiling test (whole exome and whole transcriptome, tumour and matched normal)
- Mechanism: Whole-exome DNA sequencing of the tumour and of a matched normal sample, so inherited variants can be subtracted, plus whole-transcriptome RNA sequencing of the tumour for gene fusions and selected abnormal transcripts.

## Notes

- What a result means: an alteration linked to an approved drug or a trial can widen the options after standard treatment; the matched normal sample also means some inherited findings may be flagged for confirmation.

## Sources

- Exact Sciences: OncoExTra: https://www.exactsciences.com/cancer-testing/oncoextra
- White et al., analytic validation and clinical utilization of GEM ExTra (Oncotarget 2021): https://doi.org/10.18632/oncotarget.27945

## Connected records

- biomarkers: [MSI-high (microsatellite instability by PCR or sequencing)](https://onco.cc/biomarkers/msi-high/), [NRG1 gene fusion](https://onco.cc/biomarkers/nrg1-fusion/), [NTRK1/2/3 gene fusion](https://onco.cc/biomarkers/ntrk-fusion/), [TMB-high (tumour mutational burden >= 10 mutations per megabase)](https://onco.cc/biomarkers/tmb-high/)
- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- companies: [Exact Sciences (Abbott)](https://onco.cc/companies/exact-sciences/)
- terms: [AR-V7 splice variant](https://onco.cc/terms/ar-v7/), [Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)](https://onco.cc/terms/msi/), [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/), [Tumour mutational burden (TMB)](https://onco.cc/terms/tmb/)

---
JSON: https://onco.cc/api/v1/entities/oncoextra.json